Home › Liposarcoma › New York › New York City
Liposarcoma clinical trials in New York City, NY
5 studies for Liposarcoma are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
RecruitingPhase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
RecruitingPhase 3
- Investigative Site, New York
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RecruitingPhase 3
- Laura and Issac Perlmutter Ca Ctr at NYU Langone, New York
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Liposarcoma trials in other cities
- Houston, TX10 studies
- Boston, MA7 studies
- St. Louis, MO5 studies
- Queens, NY5 studies
- Chicago, IL5 studies
- Edison, NJ4 studies
- Atlanta, GA4 studies
- Seattle, WA3 studies
- Phoenix, AZ3 studies
- Louisville, KY3 studies
- Gainesville, FL3 studies
- Richmond, VA3 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.